saquinavir and Hemophilia-A

Topics: Adult; Drug Therapy, Combination; Hemophilia A; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Liver Cirrhosis; Ritonavir; Saquinavir; Stavudine

In July 1996 the Food and Drug Administration (FDA) alerted healthcare providers about 15 case reports of spontaneous bleeding episodes in HIV-positive haemophiliacs taking HIV protease inhibitors. In order to characterize the bleeding associated with HIV protease inhibitor therapy, the FDA's spontaneous adverse event reporting system was searched through 28 February 1997. The bleeding episode reporting rate for persons with haemophilia was compared for HIV protease inhibitors and zidovudine, and the characteristics of haemorrhagic events were compared between individuals with and without haemophilia. There was a substantial predominance of bleeding episodes for haemophiliacs taking HIV protease inhibitors (39 of 67; 58%) as compared with zidovudine (two of 63; 3.2%). A comparison of 39 reports of bleeding in haemophiliacs with 28 in non-haemophiliacs revealed similarities in time to event and type of HIV protease inhibitor implicated, but differences were present concerning location of bleeding and outcome. A greater proportion of haemophiliacs had resolution of their bleeding following discontinuation of their HIV protease inhibitor and recurrence of bleeding following rechallenge, as compared with non-haemophiliacs. HIV-positive haemophiliacs appear to be at an elevated risk of bleeding while taking HIV protease inhibitors, but these medications may predispose all individuals to such complications.

Topics: Adolescent; Adult; Aged; Databases, Factual; Female; Hemophilia A; Hemorrhage; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Saquinavir; Treatment Outcome; United States; United States Food and Drug Administration; Zidovudine

Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cohort Studies; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C; HIV; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Treatment Outcome; Viral Load; Zidovudine

A stage IIIB anaplastic seminoma which occurred in an HIV-infected hemophilia is reported. The patient with hemophilia A was 36 years old and had been seropositive for HIV antibody for 3 years. Inguinal orchiectomy and subsequent chemoradiotherapy for retroperitoneal lymphadenopathy were performed and a marker negative partial response was obtained. In spite of a low initial CD4+ lymphocyte count (90/microliter), the patient tolerated the treatment well without life-threatening opportunistic infection. Although factor VIII supplement was performed, continuous bleeding from the operative wound made postoperative care difficult.

Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; CD4 Lymphocyte Count; Cisplatin; Combined Modality Therapy; Didanosine; Drug Therapy, Combination; Etoposide; Factor VIII; Germinoma; Hemophilia A; Humans; Male; Orchiectomy; Saquinavir; Testicular Neoplasms; Zidovudine